---

$94.13

+1.6360 ( +1.77% ) 10.7K

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2023-12-06	Sale	-2500.00	Howe Jolanda
2023-11-15	Sale	-527.00	Vig Pamela
2023-11-15	Sale	-434.00	Longpre Lara
2023-11-15	Sale	-218.00	Radovich Peter
2023-11-14	Buy	2910.00	Heron Patrick J
2023-09-15	Buy	2625.00	Heron Patrick J
2023-09-14	Sale	-392.00	GREY MICHAEL G
2023-09-13	Buy	4687.00	Heron Patrick J
2023-09-12	Buy	10000.00	BJERKHOLT ERIC
2023-09-05	Buy	147991.00	Heron Patrick J